A novel extracellular vesicle paradigm for the treatment of COVID-19 induced acute respiratory distress syndrome (ARDS)
Efficacy of mesenchymal stem cells (MSCs) for treatment of acute respiratory distress syndrome (ARDS) suggests bioactive bone marrow MSC extracellular vesicles (BM-MSC EVs) may be effective.A patient with severe COVID-19 associated ARDS who was presumed to expire was treated with a BM-MSC EV preparation ARC ANGEL FIRM HOLD (14 doses over two months